Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.60 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.59 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.53 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.53 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20129601 | 1.00 | GPR119 (0.60) | GPR119GRM1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL20142792 | 1.00 | GPR119 (0.60) | GPR119GRM1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL4826169 | 0.87 | GPR119 (0.58) | GPR119GRM1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL21360322 | 0.85 | GPR119 (0.56) | GPR119GRM1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL15024213 | 0.85 | GPR119 (0.61) | GPR119SMARCA2SMARCA4PBRM1POLB | |
| SCHEMBL26669788 | 0.85 | GPR119 (0.60) | GPR119GRM1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL8917888 | 0.84 | GPR119 (0.55) | GPR119GRM1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL16112856 | 0.84 | GPR119 (0.60) | GPR119GRM1GRM5POLB | |
| SCHEMBL16134968 | 0.84 | GPR119 (0.60) | GPR119GRM1GRM5POLB | |
| SCHEMBL17884743 | 0.83 | GPR119 (0.60) | GPR119SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | GPR119 2282/4885GRM1 1701/4885SMARCA2 2057/4885 |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | GPR119 2282/4885GRM1 1701/4885SMARCA2 2057/4885 |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | GPR119 2282/4885GRM1 1701/4885SMARCA2 2057/4885 |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | GPR119 2282/4885GRM1 1701/4885SMARCA2 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.